Coronavirus vaccine in China produces neutralizing antibodies in early-stage trial - CNBC
- Coronavirus vaccine in China produces neutralizing antibodies in early-stage trial CNBC
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial The Lancet
- Coronavirus vaccine gets positive results in first human trial New York Post
- Early study of Covid-19 vaccine developed in China sees mixed results STAT
- Early Coronavirus Immunity Data Fuel Promise for a Vaccine Scientific American
- View Full Coverage on Google News